HAG
PRQR icon

HighPoint Advisor Group’s ProQR Therapeutics PRQR Stock Holding History

HighPoint Advisor Group’s Portfolio PRQR Stock Details PRQR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		$99K Buy
11,850
+1,850
+19% +$12.1K 0.01% 534
2021
Q2 		$67K Buy
+10,000
New +$64.5K 0.01% 528

Other funds holding PRQR

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return

HighPoint Advisor Group's PRQR Position: Q3 2021 in Review

HighPoint Advisor Group increased its ProQR Therapeutics (PRQR) stake by 19% in Q3 2021, buying an estimated $12.1K and bringing the position to 11,850 shares worth $99K. The position accounts for 0.01% of the portfolio, ranked #534.

HighPoint Advisor Group first reported a position in PRQR in Q2 2021 and has held it in 2 quarters since. 67 funds tracked by Wall St. Rank hold PRQR as of Q3 2021.

  • HighPoint Advisor Group held 11,850 shares of ProQR Therapeutics worth $99K as of Q3 2021.
  • HighPoint Advisor Group bought 1,850 ProQR Therapeutics shares in Q3 2021, an estimated $12.1K.
  • ProQR Therapeutics made up 0.01% of HighPoint Advisor Group's portfolio in Q3 2021, its #534 holding.
  • HighPoint Advisor Group first reported a position in ProQR Therapeutics in Q2 2021 and has held it in 2 quarters since.
  • 67 funds tracked by Wall St. Rank held ProQR Therapeutics as of Q3 2021.

Based on HighPoint Advisor Group's 13F filing for Q3 2021, filed 15 Nov 2021.